Domatinostat
- Generic Name
- Domatinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21N5O3S
- CAS Number
- 910462-43-0
- Unique Ingredient Identifier
- 264ARM7UXX
- Associated Conditions
- -
- Associated Therapies
- -
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 44
- Registration Number
- NCT04133948
- Locations
- 🇳🇱
Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 75
- Registration Number
- NCT03812796
- Locations
- 🇬🇧
The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath